S Lambert-Niclot
Overview
Explore the profile of S Lambert-Niclot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
94
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fofana D, dAlmeida M, Lambert-Niclot S, Peytavin G, Girard P, Lafia B, et al.
J Antimicrob Chemother
. 2018 Jul;
73(11):3143-3147.
PMID: 30060186
Background: In Africa a high percentage of HIV-infected children continue to experience HIV treatment failure despite enormous progress. In Benin (West Africa), there are currently no data on HIV drug...
2.
Nguyen T, Fofana D, Le M, Charpentier C, Peytavin G, Wirden M, et al.
J Antimicrob Chemother
. 2018 Jun;
73(9):2485-2492.
PMID: 29873733
Background: Integrase strand transfer inhibitors (INSTIs) are recommended by international guidelines as first-line therapy in antiretroviral-naive and -experienced HIV-1-infected patients. Objectives: This study aimed at evaluating the prevalence at failure...
3.
Lambert-Niclot S, Grude M, Chaix M, Charpentier C, Reigadas S, Le Guillou-Guillemette H, et al.
J Antimicrob Chemother
. 2018 May;
73(8):2147-2151.
PMID: 29718247
Background: Atazanavir is a PI widely used as a third agent in combination ART. We aimed to determine the prevalence and the patterns of resistance in PI-naive patients failing on...
4.
Lambert-Niclot S, Allavena C, Grude M, Flandre P, Sayon S, Andre E, et al.
J Antimicrob Chemother
. 2016 May;
71(8):2248-51.
PMID: 27231280
Objectives: In the context of a rilpivirine/emtricitabine/tenofovir disoproxil fumarate switch in HIV-1-infected patients with at least 1 year of virological success, we determined whether proviral DNA is an alternative to...
5.
Soulie C, Fofana D, Boukli N, Sayon S, Lambert-Niclot S, Wirden M, et al.
J Clin Virol
. 2016 Jan;
76:51-4.
PMID: 26826578
Background: Several genotypic rules for predicting HIV-1 non-B subtypes tropism are commonly used, but there is no consensus about their performances. Objectives: Three genotypic methods were compared for CRF02_AG HIV-1...
6.
Lambert-Niclot S, George E, Pozniak A, White E, Schwimmer C, Jessen H, et al.
J Antimicrob Chemother
. 2015 Dec;
71(4):1056-62.
PMID: 26702926
Objectives: To describe the pattern of drug resistance at virological failure in the NEAT001/ANRS143 trial (first-line treatment with ritonavir-boosted darunavir plus either tenofovir/emtricitabine or raltegravir). Methods: Genotypic testing was performed...
7.
Seang S, Fourati S, Keita Y, Blanc C, Tubiana R, Schneider L, et al.
J Antimicrob Chemother
. 2014 Jul;
69(12):3356-9.
PMID: 25056835
Objectives: To evaluate whether a dual nucleoside reverse transcriptase inhibitor (NRTI) strategy can control HIV replication in antiviral therapy (ART)-naive HIV-infected patients with a high CD4 cell count and a...
8.
Fofana D, Soulie C, Balde A, Lambert-Niclot S, Sylla M, Ait-Arkoub Z, et al.
J Antimicrob Chemother
. 2014 May;
69(9):2531-5.
PMID: 24855120
Objectives: In resource-limited settings, few data are available on virological failure after long-term first-line antiretroviral therapy. This study characterized the genotypic resistance patterns at the time of failure after at...
9.
Lambert-Niclot S, Charpentier C, Storto A, Fofana D, Soulie C, Fourati S, et al.
J Antimicrob Chemother
. 2013 Dec;
69(4):1086-9.
PMID: 24302653
Objectives: In the context of simplification strategies, it is essential to know the feasibility of a switch to a rilpivirine-based therapy. The aim of this study was to describe rilpivirine,...
10.
Fofana D, Soulie C, Maiga A, Fourati S, Malet I, Wirden M, et al.
J Antimicrob Chemother
. 2013 Jul;
68(11):2515-20.
PMID: 23833185
Objectives: It has been demonstrated for some drugs that the genetic barrier, defined as the number of genetic transitions and/or transversions needed to produce a resistance mutation, can differ between...